These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23167333)

  • 21. Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk.
    Shen SQ; Jiang DK; Liu GY; Chen F; Yu L
    Mol Biol Rep; 2012 Apr; 39(4):4683-90. PubMed ID: 21952824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TP53 Arg72Pro polymorphism and skin cancer risk: a meta-analysis.
    Jiang DK; Wang WZ; Ren WH; Yao L; Peng B; Yu L
    J Invest Dermatol; 2011 Jan; 131(1):220-8. PubMed ID: 20861852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 codon 72 polymorphism and hepatocellular carcinoma: a meta-analysis.
    Jia S; Tang W; Luo Y
    Hepatol Int; 2013 Jun; 7(2):669-75. PubMed ID: 26201800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies.
    Diakite B; Kassogue Y; Dolo G; Wang J; Neuschler E; Kassogue O; Keita ML; Traore CB; Kamate B; Dembele E; Nadifi S; Murphy RL; Doumbia S; Hou L; Maiga M
    BMC Med Genet; 2020 Oct; 21(1):206. PubMed ID: 33076844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Associations between P53 Arg72Pro and development of digestive tract cancers: a meta-analysis.
    Liu L; Wang K; Zhu ZM; Shao JH
    Arch Med Res; 2011 Jan; 42(1):60-9. PubMed ID: 21376265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor necrosis factor-α 238 G/A polymorphism and risk of hepatocellular carcinoma: evidence from a meta-analysis.
    Cheng K; Zhao YJ; Liu L; Wan JJ
    Asian Pac J Cancer Prev; 2013; 14(5):3275-9. PubMed ID: 23803115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TP53 Arg72Pro polymorphism and endometrial cancer risk: a meta-analysis.
    Jiang DK; Yao L; Ren WH; Wang WZ; Peng B; Yu L
    Med Oncol; 2011 Dec; 28(4):1129-35. PubMed ID: 20552298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Updated meta-analysis of the TP53 Arg72Pro polymorphism and gastric cancer risk.
    Xiang B; Mi YY; Li TF; Liu PF
    Asian Pac J Cancer Prev; 2012; 13(5):1787-91. PubMed ID: 22901123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study of the association between five polymorphisms and risk of hepatocellular carcinoma: A meta-analysis.
    Yu JY; Hu F; Du W; Ma XL; Yuan K
    J Chin Med Assoc; 2017 Apr; 80(4):191-203. PubMed ID: 28188097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between rs738409 polymorphism in patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene and hepatocellular carcinoma susceptibility: Evidence from case-control studies.
    Li JF; Zheng EQ; Xie M
    Gene; 2019 Feb; 685():143-148. PubMed ID: 30403964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between TP53 gene codon72 polymorphism and prostate cancer risk: A systematic review and meta-analysis.
    Han PZ; Cao DH; Zhang XL; Ren ZJ; Wei Q
    Medicine (Baltimore); 2019 Jun; 98(25):e16135. PubMed ID: 31232967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P53 codon 72 polymorphism, human papillomavirus infection, and their interaction to oral carcinoma susceptibility.
    Hou J; Gu Y; Hou W; Wu S; Lou Y; Yang W; Zhu L; Hu Y; Sun M; Xue H
    BMC Genet; 2015 Jun; 16():72. PubMed ID: 26123760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases.
    Hu S; Zhao L; Yang J; Hu M
    Tumour Biol; 2014 Apr; 35(4):3647-56. PubMed ID: 24326769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of p53 Arg72Pro polymorphism with gastric cancer: a meta-analysis.
    Tang W; Zhou X; Nie S; Yang Z; Zhu H; Wu X; Zhao R; Luo Y
    Biomarkers; 2012 Nov; 17(7):597-603. PubMed ID: 22780299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between p53 Arg72Pro polymorphism and the risk of human papillomavirus-related head and neck squamous cell carcinoma: a meta-analysis.
    Xia LY; Zeng XT; Li C; Leng WD; Fan MW
    Asian Pac J Cancer Prev; 2013; 14(10):6127-30. PubMed ID: 24289637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meta-analysis of associations between ATM Asp1853Asn and TP53 Arg72Pro polymorphisms and adverse effects of cancer radiotherapy.
    Su M; Yin ZH; Wu W; Li XL; Zhou BS
    Asian Pac J Cancer Prev; 2014; 15(24):10675-81. PubMed ID: 25605158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
    Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
    Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TP53 Arg72Pro polymorphism (rs1042522) and risk of endometriosis among Asian and Caucasian populations.
    Li J; Chen Y; Mo Z; Li L
    Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():73-8. PubMed ID: 25889195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The association between cyclooxygenase-2 1195 G/A polymorphism and hepatocellular carcinoma: evidence from a meta-analysis.
    Bu X; Zhao C
    Tumour Biol; 2013 Jun; 34(3):1479-84. PubMed ID: 23494177
    [TBL] [Abstract][Full Text] [Related]  

  • 40. XRCC1 genetic polymorphism Arg399Gln and hepatocellular carcinoma risk: a meta-analysis.
    Liu F; Li B; Wei Y; Yan L; Wen T; Zhao J; Xu M
    Liver Int; 2011 Jul; 31(6):802-9. PubMed ID: 21645210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.